- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07444866
Gestión Habilitada por Aprendizaje Automático de la Intervención para Síntomas Conductuales y Psicológicos de la Demencia para Cuidadores de Personas con Demencia
Desarrollo y Prueba de una Gestión Habilitada por Aprendizaje Automático de los Síntomas Conductuales y Psicológicos de la Demencia para Cuidadores de Personas con Demencia: Un Estudio de Diseño Experimental Híbrido
Develop and test a machine learning enabled management of behavioural and psychological symptoms of dementia intervention for dementia caregivers.
Descripción general del estudio
Estado
Condiciones
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Hong Kong, Hong Kong
- The Education University of Hong Kong
-
Contacto:
- Kee Lee Chou, PhD
- Número de teléfono: +85229487473
- Correo electrónico: klchou@eduhk.hk
-
Contacto:
- Vivien Tang, MSc
- Correo electrónico: s1135125@s.eduhk.hk
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- aged 18 above
- family caregiver of an individual with a confirmed medical diagnosis of any type of dementia who has been residing in the community
- having been providing care for ADLs and IADLs for at least 20 hours per week for at least one year prior to recruitment
- have a smartphone
- have mild to moderate stress (the 14-item Chinese version Perceived Stress Scale).
Exclusion Criteria:
- having participated in any structured mind-body intervention, cognitive therapy, or structured psychosocial intervention in the 6 months prior to recruitment
- having acute psychiatric and medical comorbidities that are potentially life-threatening (e.g. suicidal ideation) or that limit the caregivers' participation or adherence (e.g. acute psychosis)
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación factorial
- Enmascaramiento: Doble
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Comparador activo: Active control
Active control |
No APP based coaching, no human coaching, no rerandomization, no MRT |
|
Experimental: App & Human Coaching + Continue Intervention
First-line of coaching: App + Human Coaching Responder |
Continue with existing intervention plan |
|
Experimental: App & Human Coaching + Increase intensity in human coaching
First-line of coaching: App + Human Coaching Non-Responder |
Increase intensity of human coaching |
|
Experimental: App & Human Coaching + Booster
First-line of coaching: App + Human Coaching Non-Responder |
Add a booster session |
|
Experimental: App Coaching + Continue Intervention
First-line of coaching: App Coaching Responder |
Continue with existing intervention plan |
|
Experimental: App Coaching + Increase intensity in human coaching
First-line of coaching: App Coaching Non-Responder |
Increase intensity of human coaching |
|
Experimental: App Coaching + Booster
First-line of coaching: App Coaching Non-Responder |
Add a booster session |
|
Experimental: Human Coaching + Continue Intervention
First-line of coaching: Human Coaching Responder |
Continue with existing intervention plan |
|
Experimental: Human Coaching + Increase intensity in human coaching
First-line of coaching: Human Coaching Non-Responder |
Increase intensity of human coaching |
|
Experimental: Human Coaching + Booster
First-line of coaching: Human Coaching Non-Responder |
Add a booster session |
|
Experimental: No Coaching + Continue Intervention
First-line of coaching: No Coaching Responder |
Continue with existing intervention plan |
|
Experimental: No Coaching + Increase intensity in human coaching
First-line of coaching: No Coaching Non-Responder |
Increase intensity of human coaching |
|
Experimental: No Coaching + Booster
First-line of coaching: No Coaching Non-Responder |
Add a booster session |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Stress
Periodo de tiempo: Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
10-item Perceived Stress Scale; each item will be rated from 0=Never to 4=Very often. Total scores range from 0 to 40. |
Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Depression
Periodo de tiempo: Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
Patient Health Questionnaire-9; Each item will be rated from 0=Not at all to 3=nearly everyday. Total scores range from 0 to 27 |
Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
|
Sleep Quality
Periodo de tiempo: Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
Pittsburgh Sleep Quality Index; each item will be rated from 0=No difficulty to 3=Severe difficulty. Total scores range from 0 to 21. Higher scores indicating poorer sleep quality |
Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
|
Anxiety
Periodo de tiempo: Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
Generalised Anxiety Disorder; each item will be rated from 0=not at all to 3=nearly every day. Total score range from 0 to 21. |
Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
|
Physical Health
Periodo de tiempo: Baseline (T0), 32 weeks after baseline assessment (T4)
|
Lawton Instrumental Activities of Daily Living; each item will be rated 0=dependent to 1=independent. Total scores range from 0 to 8. |
Baseline (T0), 32 weeks after baseline assessment (T4)
|
|
Physical Health
Periodo de tiempo: Baseline (T0), 32 weeks after baseline assessment (T4)
|
Activities of Daily Living; each item will be rate from 0=dependent to 5/10=independent. Total scores range from 0 to 100. |
Baseline (T0), 32 weeks after baseline assessment (T4)
|
|
Physical Symptoms
Periodo de tiempo: Baseline (T0), 32 weeks after baseline assessment (T4)
|
Wahler Physical Symptoms Inventory; each item will be rated from 0=almost never agree to 5=agree almost every day. Total score range from 0 to 210. |
Baseline (T0), 32 weeks after baseline assessment (T4)
|
|
Chronic Illness
Periodo de tiempo: Baseline (T0), 32 weeks after baseline assessment (T4)
|
Participants will indicate any presence of chronic illness (e.g., diabetes, asthma, high blood pressure). |
Baseline (T0), 32 weeks after baseline assessment (T4)
|
|
Caregiver Burden
Periodo de tiempo: Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
12-item Zarit Burden Interview Scale ; each item will be rated from 0=Never to 4=Nearly always. Total scores range from 0 to 48. |
Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
|
Psychological Well-Being
Periodo de tiempo: Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
18-item Ryff Psychological Well-Being scale, each item range from 1-strongly agree to 7-strongly disagree. Total score range from 18-126. |
Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
|
Physical and Mental Health
Periodo de tiempo: Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
5-level EQ-5D version (EQ-5D-5L) will be utilized; the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. The EQ VAS records the patient's self-rated health on a vertical visual analogue scale where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. The VAS can be used as a quantitative measure of health outcome that reflects |
Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
|
Neuropsychiatric
Periodo de tiempo: Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
Neuropsychiatric Inventory Questionnaire; classified each of the 12 domain into presence of symptom, frequency, severity, and caregiver distress. |
Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
|
Memory and Behaviour Problems
Periodo de tiempo: Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
Revised Memory and Behavior Problems Checklist; a 24-item checklist from 0=never occurred/not at all to 4=daily/extremely. Higher score indicate more frequent behavioral problems/caregiver distress |
Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Caregiving
Periodo de tiempo: Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
Revised Scale for Caregiving Self-efficacy; 15-item scale. Total score is 100. |
Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Kee Lee Chou, PhD, The Education University of Hong Kong
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Otros números de identificación del estudio
- 2023-2024-0387
- 22231921 (Otro número de subvención/financiamiento: Research Fund Secretariat, Health Bureau)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .